American Journal of Rhinology & Allergy
The American Journal of Rhinology & Allergy is a peer reviewed, scientific publication committed to expanding knowledge and publishing the best clinical and basic research within the fields of rhinology & allergy. Its focus is to publish information which contributes to improved quality of care for patients with nasal and sinus disorders. Its primary readership consists of otolaryngologists, allergists, and plastic surgeons. Published material includes peer reviewed original research, clinical trials, and review articles. The journal uses double anonymized peer review in which the reviewer's name is withheld from the author and, the author's name from the reviewer.
| Raj Sindwani, MD | Cleveland Clinic Foundation, Cleveland, OH, USA |
| Rakesh Chandra, MD | Co-Editor-in-Chief, 2010–2019 |
| Anju Peters, MD | Deputy Editor, 2014–2017, Co-Editor-in-Chief, 2018–2019 |
| Alex Chiu, MD | Co-Editor-in-Chief, 2010–2015 |
| David Kennedy, MD | Editor-in-Chief, 2004–2010, Co-Editor-in-Chief, 1991–2003 |
| Phil Fireman, MD | Co-Editor-in-Chief, 1991–2003 |
| Larry E. Duberstein, MD | Co-Editor-in-Chief, 1987–1991 |
| John Connell, MD | Co-Editor-in-Chief, 1987–1991 |
| A. Simon Carney, MD | Flinders University, Adelaide, Australia |
| Seong Cho, MD | University of South Florida, Tampa, FL, USA |
| Cemal Cingi, MD | Eskisehir Osmangazi University, Eskisehir, Turkey |
| Edward Kuan, MD | University of California Irvine, Irvine, CA, USA |
| Devyani Lal, MD | Mayo Clinic, Phoenix, AZ, USA |
| Andrew Lane, MD | Johns Hopkins, Baltimore, MA, USA |
| Stella Lee, MD | Harvard Medical School, Boston, MA, USA |
| Mahboobeh Mahdavinia, MD | Northwestern University Feinberg School of Medicine, Chicago, IL, USA |
| Douglas Reh, MD | Ear, Nose & Throat Associates, Baltimore, MD, USA |
| Marc R. Rosen, MD | Thomas Jefferson University, PA, USA |
| Christina Schwindt, MD | Allergy and Asthma Associates, Southern CA Research, Mission Viejo, CA, USA |
| Janalee Stokken, MD | Mayo Clinic, Rochester, MN, USA |
| Tetsuji Takabayashi, MD, PhD | University of Fukui, Fukui, Japan |
| Eric Wang, MD | University of Pittsburgh Medical Center, Pittsburgh, PA, USA |
| Ian Witterick, MD | University of Toronto, Toronto, ON, Canada |
| Bradford Woodworth, MD | The University of Alabama at Birmingham, Birmingham, AL, USA |
| Bozena Wrobel, MD | University of Southern CA, Los Angeles, CA, USA |
| Vijay Anand, MD | Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, USA |
| Ben Bleier, MD | Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, MA, USA |
| Larry Borish, MD | University of Virginia, Charlottesville, VA, USA |
| Karen Calhoun, MD | Ohio State University Wexner Medical Center, Columbus, OH, USA |
| Tara Carr, MD | University of Arizona, Tucson, AZ, USA |
| Warner Carr, MD | Allergy and Asthma Associates, Southern CA Research, Mission Viejo, CA, USA |
| Ricardo Carrau, MD | Ohio State University Wexner Medical Center, Columbus, OH, USA |
| Roy Casiano, MD | University of Miami Health System, Miami, FL, USA |
| Marco Caversaccio, MD | University Hospital Bern, Bern, Switzerland |
| Bradley Chipps, MD | Capital Allergy & Respiratory, Sacramento, CA, USA |
| Alex Chiu, MD | University of Kansas Medical Center, Kansas City, KS, USA |
| Martin Citardi, MD | University of TX Medical School at Houston, Houston, TX,USA |
| Mark Corbett, MD | Allergy & Immunology, Louisville, KY, USA |
| Jacquelynne Corey, MD | University of Chicago, Chicago, IL, USA |
| Chris DeSouza, MD | Holy Family Hospital, Mumbai, India |
| Hun-Jong Dhong, MD | Sungkyunkwan Kwan University School of Medicine, Seoul, Korea |
| Mark Dykewicz, MD | SSM Health St. Louis University Hospital, St. Louis, MO, USA |
| Jean Anderson Eloy, MD | Rutgers New Jersey Medical School, Newark, NJ, USA |
| Alan Gaines, MD | Warren Alpert Medical School, Brown University, Providence, RI Island, USA |
| Balwant Singh Gendeh, MD | National University of Malaysia, Kuala Lumpur, Malaysia |
| Christos Georgalas, MD | Hygeia Hospital, Athens, Greece |
| Stacey Gray, MD | Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA |
| Dan Hamilos, MD | Massachusetts General Hospital, Boston, MA, USA |
| Richard Harvey, MD | St. Vincent's Hospital, Sydney, Sydney, Australia |
| Ashutosh Kacker, MD | NYP/Weill Cornell Medical Center, New York, NY, USA |
| Michael Kaliner, MD | Institute for Asthma & Allergy, Bethesda, MD, USA |
| Robert Kern, MD | Northwestern University, Chicago, IL, USA |
| Jivianne Lee, MD | Sinus Institute of Orange County, Irvine, CA, USA |
| John Lee, MD | University of Toronto, Toronto, ON, Canada |
| Wolf Mann, MD | University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany |
| Eli Meltzer, MD | Allergy & Asthma Medical Group and Research Center, San Diego, CA, USA |
| Ralph Metson, MD | Massachusetts Eye and Ear Infirmary, Boston, MA, USA |
| Michael Nelson, MD | Walter Reed Army Medical Center, Washington, DC, USA |
| Jim Palmer, MD | University of Pennsylvania, Philadelphia, PA, USA |
| Ruby Pawankar, MD | Nippon Medical School, Tokyo, Japan |
| David Poetker, MD | Medical College of Wisconsin, Milwaukee, WI, USA |
| Alkis Psaltis, MD | University of Adelaide, Woodville, South Australia |
| Matthew Rank, MD | Mayo Clinic, Scottsdale, AZ, USA |
| Ray Sacks, MD | ENT Clinic, Sydney, Australia |
| Rodney Schlosser, MD | Medical University of South Carolina, Charleston, SC, USA |
| Raymond Slavin, MD | Saint Louis University School of Medicine, St. Louis, MO, USA |
| Carl Snyderman, MD | University of Pittsburgh School of Medicine, Pittsburgh, PA, USA |
| Jeff Suh, MD | University of CA, Los Angeles, Los Angeles, CA, USA |
| Justin Turner, MD | Vanderbilt University Medical Center, Nashville, TN, USA |
| De Yun Wang, MD | National University of Singapore, Singapore |
| Dehui Wang, MD | Eye, Ear, Nose and Throat Hospital, Shanghai, China |
| Sarah Wise, MD | Emory University, Atlanta, GA, USA |
| Troy Woodard, MD | Cleveland Clinic, Cleveland, OH, USA |
| Erin Wright, MD | University of Alberta, Edmonton, AB, Canada |
Manuscript Submission Guidelines: American Journal of Rhinology & Allergy
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the Journal’s submission site https://mc.manuscriptcentral.com/ajra to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.
Only manuscripts of sufficient quality that meet the aims and scope of American Journal of Rhinology & Allergy will be reviewed.
There are no fees payable to submit or publish in this Journal. Open Access options are available - see section 3.3 below.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that American Journal of Rhinology & Allergy may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.
If you have any questions about publishing with Sage, please visit the Sage Journal Solutions Portal
- What do we publish?
1.1 Aims & Scope
1.2 Article types
1.3 Writing your paper - Editorial policies
2.1 Peer review policy
2.2 Authorship
2.3 Acknowledgements
2.4 Funding
2.5 Declaration of conflicting interests
2.6 Research ethics and patient consent
2.7 Clinical trials
2.8 Reporting guidelines
2.9 Research Data - Publishing policies
3.1 Publication ethics
3.2 Contributor's publishing agreement
3.3 Open access and author archiving
3.4 Plain Language Summaries - Preparing your manuscript for submission
4.1 Formatting
4.2 Artwork, figures and other graphics
4.3 Supplemental material
4.4 Reference style
4.5 English language editing services - Submitting your manuscript
5.1 ORCID
5.2 Information required for completing your submission
5.3 Permissions - On acceptance and publication
6.1 Sage Production
6.2 Online First publication
6.3 Access to your published article
6.4 Promoting your article
1. What do we publish?
Before submitting your manuscript to American Journal of Rhinology & Allergy, please ensure you have read the Aims & Scope.
American Journal of Rhinology & Allergy publishes peer-reviewed original laboratory and/or clinical research (2,500 words), reviews (3,000 words), letters to the editor (500 words and 5 references), solicited meeting papers (2,500 words), and solicited “How I Do It” papers (200 word abstract, 750 words, and 5 references). Note: Word counts do not include abstracts and references.
Additional information for solicited manuscripts:
Meeting papers: The corresponding scientific meeting should be included on the title page in the format of the name of the meeting, city, state (or country), date of meeting (i.e. “Presented at the North American Rhinology & Allergy Conference, St. Thomas, Virgin Islands, January 14, 2016”)
“How I Do It” papers: Solicited submissions should report on novel and cutting edge techniques addressing clinical problems within the fields of allergy and rhinology. Submissions should enable the reader to both understand the problem and replicate the technique if they so choose. Preference will be given to submissions with high quality figures and videos.
Format for “How I Do It” solicited submissions:
Abstract: Up to 200 words
Sections: Introduction, Materials and Methods, Results, Discussion, Conclusion
Word Count: Approximately 750 words and up to 5 references
Figures: 1-3 still high quality photos, ~1 MB, accepted formats include .tif, .jpeg, .eps
Tables: up to 2 tables
Video 3-5MB, Narration preferred, formats accepted Quick Time Movie (.mov) or Windows Media Video (.wmv)
American Journal of Rhinology & Allergy generally does not accept case reports for publication. Case reports that are truly unique and have an exceptional teaching value will be referred to the open access journal, Allergy & Rhinology, for consideration
The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.
1.3.1 Make your article discoverable
When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online
2. Editorial policies
Sage does not permit the use of author-suggested (recommended) reviewers at any stage of the submission process, be that through the web-based submission system or other communication.
Reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Our policy is that reviewers should not be assigned to a paper if:
- The reviewer is based at the same institution as any of the co-authors.
- The reviewer is based at the funding body of the paper.
- The author has recommended the reviewer.
- The reviewer has provided a personal (e.g. Gmail/Yahoo/Hotmail) email account and an institutional email account cannot be found after performing a basic Google search (name, department and institution).
AJR is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third-party service that seeks to track, verify and give credit for peer review. Reviewers for AJR can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the Journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Beginning January 1, 2023 AJR operates a strictly anonymized peer review process in which the reviewer’s name is withheld from the author and, the author’s name from the reviewer. To enable this when uploading your manuscript will you will need to upload a manuscript file with NO IDENTIFYING AUTHOR INFORMATION (designate as Main Document) and a separate title page (designate as Title Page) with author details.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
(ii) Drafted the article or revised it critically for important intellectual content,
(iii) Approved the version to be published,
(iv) Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
• Disclose this type of editorial assistance – including the individual’s name, company and level of input
• Identify any entities that paid for this assistance
• Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
2.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
American Journal of Rhinology & Allergy requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
2.5 Declaration of conflicting interests
It is the policy of American Journal of Rhinology & Allergy to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here.
2.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
Authors need to include an ethical approval statement in the Title Page, with the correct statement completed:
(i) Ethical approval for this study was obtained from *NAME OF ETHICS COMMITTEE OR INSTITUTIONAL REVIEW BOARD (APPROVAL NUMBER/ID)*.
Or
(ii) Ethical approval for this study was waived by *NAME OF ETHICS COMMITTEE OR INSTITUTIONAL REVIEW BOARD* because *REASON FOR WAIVER*.
Or
(iii) Ethical approval was not sought for the present study because *REASON*.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
American Journal of Rhinology & Allergy conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
- share your research data in a relevant public data repository
- include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
- cite this data in your research
Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway
3.1.1 Plagiarism
American Journal of Rhinology & Allergy and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
3.1.2 Prior publication
If material has been previously published it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.
3.2 Contributor's publishing agreement
Before publication, Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Sage’s Journal Contributor’s Publishing Agreement is an exclusive license agreement which means that the author retains copyright in the work but grants Sage the sole and exclusive right and license to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than Sage. In this case copyright in the work will be assigned from the author to the society. For more information please visit the Sage Author Gateway
3.3 Open access and author archiving
American Journal of Rhinology & Allergy offers optional open access publishing via the Sage Choice programme and Open Access agreements, where authors can publish open access either discounted or free of charge depending on the agreement with Sage. Find out if your institution is participating by visiting Open Access Agreements at Sage. For more information on Open Access publishing options at Sage please visit Sage Open Access. For information on funding body compliance, and depositing your article in repositories, please visit Sage’s Author Archiving and Re-Use Guidelines and Publishing Policies.
A plain language summary (PLS) is an optional addition that can be submitted for any article type that requires an abstract. The plain language title (approx. 50 words) and plain language summary (approx. 300 words) should describe the article using non-technical language, making it accessible to a wider network of readers. More information and guidance on how to write a PLS can be found on our Author Gateway.
The PLS publishes directly below the scientific abstract and are open access making it available online for anyone to read. Peer review of the PLS will be conducted following our PLS reviewer guidelines. When submitting, authors should enter their plain language title and plain language summary into the box provided in the submission system when prompted. The PLS does not need to be provided in the manuscript text or as a separate file. If you are not submitting a PLS with your submission, please enter “N/A” in each box.
If you need professional help writing your Plain Language Summary, please visit our Author Services portal.
4. Preparing your manuscript for submission
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
1. Cover letter:
• Declare intentions to publish in AJRA and confirm you have not submitted elsewhere
2. Title page:
• Include full a non-declarant, relevant, and concise title in sentence format (only capitalize proper nouns). Do not include abbreviations or use trade names in the title.
• First name, middle initial, last name of each author with highest academic degrees included (do not include fellowships). All contributing authors should be listed including any professional writing assistance.
• Name of Departments and Institutions to which work should be attributed
• Disclaimers if any should be limited to those pertaining to this work.
• If this work is supported through NIH funding, this must be noted in the footnote.
• Keywords (10 key words are mandatory) Selecting appropriate keywords is essential to your research being discovered by others. Keywords should be mentioned in the abstract.
• Include date of presentation at scientific meeting (if any).
• Include corresponding author’s telephone number and e-mail address.
3. Abstract: All manuscript types with the exception of the Letters to the Editors should include a structured abstract, no longer than 300 words, to precede article. Only include acronyms or abbreviations if the phrase appears more than three times in the abstract. The abstract should NOT contain brand names, trademarks or references. Clinical trial registration numbers should be listed last in the abstract. Structure abstract into the following sections:
Background – Describe the problem that prompted the study
Objective – Describe the purpose of the study
Methods – Describe how the study was conducted
Results – Describe the most important findings
Conclusion – Describe the most important conclusion drawn from the study
Text: Manuscript should be typed double-spaced in a standard font such as Times New Roman, Arial, Courier, or Helvetica, in size 12. Text should be written in clear and concise English with proper use of grammar and syntax. Please add line numbers to your text so that reviewers can most accurately direct their feedback.
4. Acknowledgment: General acknowledgments for consultations, statistical analysis and such should be listed at the end of the text before the References. Include full names of individuals.
5. References (described below)
6. Tables, Figures, Illustrations (described below)
4.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines
Figures supplied in color will appear in color online regardless of whether or not these illustrations are reproduced in color in the printed version. For specifically requested color reproduction in print, you will receive information regarding the costs from Sage after receipt of your accepted article.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files
American Journal of Rhinology & Allergy adheres to the Sage Vancouver reference style. View the Sage Vancouver guidelines to ensure your manuscript conforms to this reference style.
If you use EndNote to manage references, you can download the Sage Vancouver EndNote output file
4.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.
American Journal of Rhinology & Allergy is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/ajra to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID ID you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.
5.2 Information required for completing your submission
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway
6. On acceptance and publication
Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be sent by PDF to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.
Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the Sage Journals help page for more details, including how to cite Online First articles.
6.3 Access to your published article
Sage provides authors with online access to their final article.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.